Want to join the conversation?
In 3Q15, $TMO's Academic and Government businesses grew in the low single digits. Conditions in these end-markets were also basically similar to what it experienced in 2Q15. $TMO's Pharma and Biotech end-markets grew just over 10% during the quarter by effectively leveraging the company's unique value proposition.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.